216 related articles for article (PubMed ID: 28366707)
1. Relative effects of antiretroviral therapy and harm reduction initiatives on HIV incidence in British Columbia, Canada, 1996-2013: a modelling study.
Nosyk B; Zang X; Min JE; Krebs E; Lima VD; Milloy MJ; Shoveller J; Barrios R; Harrigan PR; Kerr T; Wood E; Montaner JSG
Lancet HIV; 2017 Jul; 4(7):e303-e310. PubMed ID: 28366707
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of population-level expansion of highly active antiretroviral treatment for HIV in British Columbia, Canada: a modelling study.
Nosyk B; Min JE; Lima VD; Hogg RS; Montaner JS;
Lancet HIV; 2015 Sep; 2(9):e393-400. PubMed ID: 26423553
[TBL] [Abstract][Full Text] [Related]
3. Modelling integrated antiretroviral treatment and harm reduction services on HIV and overdose among people who inject drugs in Tijuana, Mexico.
Cepeda JA; Bórquez A; Magana C; Vo A; Rafful C; Rangel G; Medina-Mora ME; Strathdee S; Martin NK
J Int AIDS Soc; 2020 Jun; 23 Suppl 1(Suppl 1):e25493. PubMed ID: 32562375
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine.
Alistar SS; Owens DK; Brandeau ML
PLoS Med; 2011 Mar; 8(3):e1000423. PubMed ID: 21390264
[TBL] [Abstract][Full Text] [Related]
5. HIV treatment as prevention among people who inject drugs - a re-evaluation of the evidence.
Fraser H; Mukandavire C; Martin NK; Hickman M; Cohen MS; Miller WC; Vickerman P
Int J Epidemiol; 2017 Apr; 46(2):466-478. PubMed ID: 27524816
[TBL] [Abstract][Full Text] [Related]
6. The Cost-Effectiveness of Human Immunodeficiency Virus Testing and Treatment Engagement Initiatives in British Columbia, Canada: 2011-2013.
Nosyk B; Min JE; Krebs E; Zang X; Compton M; Gustafson R; Barrios R; Montaner JSG;
Clin Infect Dis; 2018 Feb; 66(5):765-777. PubMed ID: 29028964
[TBL] [Abstract][Full Text] [Related]
7. Expanding HAART treatment to all currently eligible individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada.
Lima VD; Hogg RS; Montaner JS
PLoS One; 2010 Jun; 5(6):e10991. PubMed ID: 20539817
[TBL] [Abstract][Full Text] [Related]
8. Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study.
Cepeda JA; Eritsyan K; Vickerman P; Lyubimova A; Shegay M; Odinokova V; Beletsky L; Borquez A; Hickman M; Beyrer C; Martin NK
Lancet HIV; 2018 Oct; 5(10):e578-e587. PubMed ID: 30033374
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Treatment as Prevention on the HIV Epidemic in British Columbia, Canada.
Lima VD; Brumme ZL; Brumme C; Sereda P; Krajden M; Wong J; Guillemi SA; Henry B; Hogg RS; Barrios R; Montaner JSG;
Curr HIV/AIDS Rep; 2020 Apr; 17(2):77-87. PubMed ID: 32124189
[TBL] [Abstract][Full Text] [Related]
10. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
[TBL] [Abstract][Full Text] [Related]
11. Controlling HIV among people who inject drugs in Eastern Europe and Central Asia: insights from modeling.
Vickerman P; Platt L; Jolley E; Rhodes T; Kazatchkine MD; Latypov A
Int J Drug Policy; 2014 Nov; 25(6):1163-73. PubMed ID: 25449056
[TBL] [Abstract][Full Text] [Related]
12. AIDS incidence and AIDS-related mortality in British Columbia, Canada, between 1981 and 2013: a retrospective study.
Lima VD; Lourenço L; Yip B; Hogg RS; Phillips P; Montaner JS
Lancet HIV; 2015 Mar; 2(3):e92-7. PubMed ID: 25780802
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States.
Long EF; Brandeau ML; Owens DK
Ann Intern Med; 2010 Dec; 153(12):778-89. PubMed ID: 21173412
[TBL] [Abstract][Full Text] [Related]
14. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study.
Montaner JS; Lima VD; Barrios R; Yip B; Wood E; Kerr T; Shannon K; Harrigan PR; Hogg RS; Daly P; Kendall P
Lancet; 2010 Aug; 376(9740):532-9. PubMed ID: 20638713
[TBL] [Abstract][Full Text] [Related]
15. A historical review of HIV prevention and care initiatives in British Columbia, Canada: 1996-2015.
Olding M; Enns B; Panagiotoglou D; Shoveller J; Harrigan PR; Barrios R; Kerr T; Montaner JSG; Nosyk B
J Int AIDS Soc; 2017 Sep; 20(1):21941. PubMed ID: 28953322
[TBL] [Abstract][Full Text] [Related]
16. Maximizing the benefits of antiretroviral therapy for key affected populations.
Grubb IR; Beckham SW; Kazatchkine M; Thomas RM; Albers ER; Cabral M; Lange J; Vella S; Kurian M; Beyrer C;
J Int AIDS Soc; 2014; 17(1):19320. PubMed ID: 25043380
[TBL] [Abstract][Full Text] [Related]
17. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Buxton JA; Wong J; Tyndall MW; Janjua NZ;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):200-210. PubMed ID: 28404135
[TBL] [Abstract][Full Text] [Related]
18. The potential impact of expanding antiretroviral therapy and combination prevention in Vietnam: towards elimination of HIV transmission.
Kato M; Granich R; Bui DD; Tran HV; Nadol P; Jacka D; Sabin K; Suthar AB; Mesquita F; Lo YR; Williams B
J Acquir Immune Defic Syndr; 2013 Aug; 63(5):e142-9. PubMed ID: 23714739
[TBL] [Abstract][Full Text] [Related]
19. Reductions in all-cause and cause-specific mortality among HIV-infected individuals receiving antiretroviral therapy in British Columbia, Canada: 2001-2012.
Cheung CC; Ding E; Sereda P; Yip B; Lourenco L; Barrios R; Montaner J; Hogg RS; Lima V; Moore DM
HIV Med; 2016 Oct; 17(9):694-701. PubMed ID: 27279453
[TBL] [Abstract][Full Text] [Related]
20. Non-medically supervised treatment interruptions among participants in a universally accessible antiretroviral therapy programme.
Moore DM; Zhang W; Yip B; Genebat M; Lima VD; Montaner JS; Hogg RS
HIV Med; 2010 May; 11(5):299-307. PubMed ID: 20002777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
